Next Article in Journal
Periodontal Wound Healing and Tissue Regeneration: A Narrative Review
Next Article in Special Issue
Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis
Previous Article in Journal
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
Previous Article in Special Issue
Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44+CD24 Sorted MDA-MB-231 Cells by Cisplatin
Review

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive

Translational Oncology Laboratory, Avera Cancer Institute, Sioux Falls, SD 57105, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Maryam Nakhjavani and Amanda Townsend
Pharmaceuticals 2021, 14(5), 455; https://doi.org/10.3390/ph14050455
Received: 15 April 2021 / Revised: 28 April 2021 / Accepted: 7 May 2021 / Published: 12 May 2021
Metastatic triple-negative breast cancer (TNBC) is a distinct and immensely complex form of breast cancer. Among all subtypes of breast cancers, TNBC has a comparatively high rate of relapse, a high rate of distant metastasis, and poor overall survival after standard chemotherapy. Chemotherapy regimens are an essential component of the management of this estrogen receptor-negative, progesterone receptor-negative, and epidermal growth factor receptor2 negative subtype of breast cancers. Chemotherapy is critical for preventing the recurrence of the disease and for achieving long-term survival. Currently, a couple of agents are approved for the management of this disease, including chemotherapy like eribulin, targeted therapy like PARP inhibitor, as well as an antibody-drug conjugate (ADC) to target TROP2. Like many other metastatic cancers, immune checkpoint inhibitors (ICIs) have also been approved for TNBC patients with PD-L1 positive tumors and high tumor mutational burden. In this review article, we discuss these newly approved and promising novel agents that may change the therapeutic landscape for advanced/metastatic TNBC patients. View Full-Text
Keywords: triple-negative breast cancer (TNBC); targeted therapy; immunotherapy triple-negative breast cancer (TNBC); targeted therapy; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Nandini, D.; Jennifer, A.; Pradip, D. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. Pharmaceuticals 2021, 14, 455. https://doi.org/10.3390/ph14050455

AMA Style

Nandini D, Jennifer A, Pradip D. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive. Pharmaceuticals. 2021; 14(5):455. https://doi.org/10.3390/ph14050455

Chicago/Turabian Style

Nandini, Dey, Aske Jennifer, and De Pradip. 2021. "Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive" Pharmaceuticals 14, no. 5: 455. https://doi.org/10.3390/ph14050455

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop